| Literature DB >> 24083375 |
Abraham S Alabi1, Lisa Frielinghaus, Harry Kaba, Katrin Kösters, Michaëla A M Huson, Barbara C Kahl, Georg Peters, Martin P Grobusch, Saadou Issifou, Peter G Kremsner, Frieder Schaumburg.
Abstract
BACKGROUND: Physicians depend on reliable information on the local epidemiology of infection and antibiotic resistance rates to guide empiric treatment in critically ill patients. As these data are scarce for Central Africa, we performed a retrospective analysis of microbiological findings from a secondary care hospital in Gabon.Entities:
Mesh:
Year: 2013 PMID: 24083375 PMCID: PMC3849904 DOI: 10.1186/1471-2334-13-455
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic characteristics of the study population
| Patients, n (%) | 2009 | 60 (9.4) | 91 (23.0) |
| | 2010 | 132 (20.8) | 79 (20.0) |
| | 2011 | 235 (37.0) | 111 (28.1) |
| | 2012 | 209 (32.9) | 114 (28.9) |
| | Total | 636 (100) | 395 (100) |
| Sex, n (%) | Female | 289 (46.5) | 263 (70.5) |
| Mean age in years (range) | | 3.6 (0–18) | 37.8 (18.3-89.7) |
| No of different species per patient (± SD) | 1.1 (0.48) | 1.3 (0.68) |
Distribution of isolates from various infections
| Bloodstream infection | 126 (17.0) | 81 (15.3) | 1.1 (0.8-1.6) | 0.4 |
| Ear, eye, nose, throat infection | 167 (22.6) | 6 (1.1) | 25.5 (11.3-70.9) | <0.0005 |
| Surgical site infection | 35 (4.7) | 106 (20.0) | 0.2 (0.1-0.3) | <0.0005 |
| Skin and soft tissue infection | 155 (21.0) | 37 (7.0) | 3.5 (2.4-5.3) | <0.0005 |
| Urinary tract infection | 70 (9.5) | 94 (17.7) | 0.5 (0.3-0.7) | <0.0005 |
| Wound infection | 76 (10.3) | 68 (12.8) | 0.8 (0.5-1.1) | 0.2 |
| Others | 111 (15.0) | 139 (26.2) | 0.5 (0.4-0.7) | <0.0005 |
| Total | 740 (100) | 531 (100) | - | - |
The three most frequent pathogens from major infections in Gabonese children and adults
| Bloodstream infection | 21 (16.7) | - | |
| | 15 (11.9) | 15 (18.5) | |
| | 14 (11.1) | 12 (14.8) | |
| | - | 10 (12.4) | |
| | Others | 76 (59.5) | 44 (54.3) |
| Ear, eye, nose, throat infection | 37 (22.2) | 1 (16.7) | |
| | 15 (9.0) | 1 (16.7) | |
| | 14 (8.4) | 1 (16.7) | |
| | Others | 101 (60.5) | 3 (50.0) |
| Surgical site infection | 9 (25.7) | 33 (32.0) | |
| | - | 15 (14.2) | |
| | 6 (17.1) | - | |
| | 4 (11.4) | 7 (6.6) | |
| | Others | 16 (45.7) | 51 (48.1) |
| Skin and soft tissue infection | 116 (74.8) | 28 (75.7) | |
| | 31 (20.0) | 1 (2.7) | |
| | 2 (1.3) | 2 (5.4) | |
| | Others | 6 (3.9) | 6 (16.2) |
| Urinary tract infection | 28 (40.0) | 36 (38.3) | |
| | 9 (12.9) | 4 (4.3) | |
| | 4 (5.7) | 19 (20.2) | |
| | Others | 29 (41.4) | 35 (37.2) |
| Wound infection | 35 (46.1) | 15 (22.1) | |
| | 20 (26.3) | - | |
| | 7 (9.2) | - | |
| | - | 8 (11.8) | |
| | - | 8 (11.8) | |
| Others | 14 (18.4) | 37 (54.4) |
Non-susceptibility rates of the most prevalent bacterial pathogens from bloodstream infections in Gabon
| 89.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 7.8 | 66.7 | |
| 0 | - | - | 0 | - | - | ND | 0 | 0 | 0 | - | |
| 25 | - | - | 25 | - | - | 33.3 | 14.3 | 13.3 | 71.4 | ND | |
| 100 | - | 92.6 | 74.1 | 75 | 37.9 | 100 | - | - | 96.3 | ND | |
| 90.9 | - | 81.8 | 80 | 45.4 | 18.2 | 50 | - | - | 80 | ND | |
| 81.2 | - | 62.5 | 0 | 6.3 | 12.5 | 66.7 | - | - | 81.2 | ND | |
| 3.9 | - | 3.9 | 3.9 | 0 | 0 | 11.1 | - | - | 4 | 0 | |
Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin plus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN), ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates are shown as the percentage of tested isolates. Data from P. aeruginosa and P. mirabilis were not reported due to small sample size (n = 2).
aShown is the non-susceptibility of Gram-positives to penicillin and the non-susceptibility of Gram-negatives to ampicillin.
Non-susceptibility rates of the most prevalent non-invasive bacterial pathogens from Gabon
| 94.2 | 8.33 | 8.33 | 8.33 | 2.3 | 9.4 | 0.9 | 2.5 | 17.0 | 8.3 | 37.5 | |
| 8.6 | - | - | 0 | - | - | 9.1 | 7.8 | 7.9 | 56.0 | - | |
| 6.7 | - | - | ND | - | - | 14.3 | 10.5 | 11.1 | 82.4 | ND | |
| 0 | - | - | - | - | 81.3 | - | - | - | - | - | |
| 100 | - | 51.9 | 38.9 | 38.2 | 21.4 | 55.6 | - | - | 60 | ND | |
| 83.3 | - | 75.5 | ND | 0 | 0 | ND | - | - | 0 | ND | |
| - | - | 0b | 0c | 0d | 2.6 | - | - | - | - | - | |
| 34.6 | - | 17.3 | 2.1 | 13.5 | 1.9 | 44.4 | - | - | 48.9 | ND | |
| 80.4 | - | 60.3 | 16.4 | 14.7 | 24.1 | 35.5 | - | - | 88.1 | ND | |
| 22.2 | - | ND | 0 | 0 | 0 | 0 | - | - | 12.5 | 0 | |
Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin plus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN), ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates are shown as the percentage of tested isolates.
aShown is the non-susceptibility of Gram-positives to penicillin and the non-susceptibility of Gram-negatives and E. faecalis to ampicillin.
bNon-susceptibility to piperacillin/tazobactam.
cNon-susceptibility to ceftazidim.
dNon-susceptibility to amikacin.